Influence of Non-Toxic Doses of Bevacizumab and Ranibizumab on Endothelial Functions and Inhibition of Angiogenesis

REFERENCES

• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–858.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–857.
   PubMed Web of Science ®Google Scholar
• Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32:1–14.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–372, e365.
   PubMed Web of Science ®Google Scholar
• Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy. Br J Ophthalmol. 2008;92:866–867.
   PubMedGoogle Scholar
• Klettner A, Roider J. Comparison of Bevacizumab, ranibizumab, and pegaptanib in vitro: Efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523–4527.
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of Bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316–1321.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Parravicini C, Sironi M, et al. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: Implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci U S A. 1994;91:7291–7295.
   PubMed Web of Science ®Google Scholar
• Barzelay A, Ben-Shoshan J, Entin-Meer M, Maysel-Auslender S, Afek A, Barshack I, Keren G, George J. A potential role for islet-1 in post-natal angiogenesis and vasculogenesis. Thromb Haemostasis. 2010;103(1):188–197. Epub 2009 Oct 26.
   PubMedGoogle Scholar
• Ben-Shoshan J, Maysel-Auslender S, Luboshits G, et al. Hypoxia-inducible factor-1alpha and -2alpha additively promote endothelial vasculogenic properties. J Vasc Res. 2009;46:299–310.
   PubMedGoogle Scholar
• Ben-Shoshan J, Schwartz S, Luboshits G, et al. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells. 2008;26:2634–2643.
   PubMedGoogle Scholar
• Kim BS, Mooney DJ. Engineering smooth muscle tissue with a predefined structure. J Biomed Mater Res. 1998;41:322–332.
   PubMed Web of Science ®Google Scholar
• Bouhadir KH, Mooney DJ. In vitro and in vivo models for the reconstruction of intercellular signaling. Ann N Y Acad Sci. 1998;842:188–194.
   PubMed Web of Science ®Google Scholar
• Gien J, Seedorf GJ, Balasubramaniam V, et al. Intrauterine pulmonary hypertension impairs angiogenesis in vitro: Role of vascular endothelial growth factor nitric oxide signaling. Am J Respir Crit Care Med. 2007;176:1146–1153.
   PubMedGoogle Scholar
• Bischoff J. Cell Adhesion and Angiogenesis. J Clin Invest. 1997;99:373–376.
   PubMedGoogle Scholar
• Vacca A, Iurlaro M, Ribatti D, et al. (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143–4155.
   PubMed Web of Science ®Google Scholar
• Vailhe B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest. 2001;81:439–452.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Brooks PC, Shaffer RW, et al. (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500–1502.
   PubMed Web of Science ®Google Scholar
• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–660.
   PubMed Web of Science ®Google Scholar
• Zacharek A, Chen J, Cui X, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab. 2007;27:1684–1691.
   PubMed Web of Science ®Google Scholar
• Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835–846.
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of Bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814–2823.
   PubMed Web of Science ®Google Scholar
• Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of Bevacizumab (Avastin). Retina. 2006;26:262–269.
   PubMed Web of Science ®Google Scholar
• Zhao B, Ma A, Cai J, et al. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol. 2006;90:1052–1059.
   PubMed Web of Science ®Google Scholar
• Kurzen H, Schmitt S, Naher H, et al. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs. 2003;14:515–522.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870.
   PubMed Web of Science ®Google Scholar
• Costa RCA, Rocha A, Pirraco A, et al. Bevacizumab and Ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem. 2009;108:1410–1417.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
   PubMed Web of Science ®Google Scholar
• Daniel F Martin, The Cleveland Clinic, Stuart L Fine, MD, Study Vice-Chair, University of Pennsylvania, Maureen G Maguire, PhD, Director of Coordinating Center, University of Pennsylvania, Glenn Jaffe, MD, Director of OCT Reading Center, Duke University, Juan E Grunwald, MD, Principal Investigator of Photography Reading Center, Universisty of Pennsylvania. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial. Retrieved March 23, 2010, from http://clinicaltrials.gov/ct2/show/NCT00593450.
   Google Scholar
• Daniel F Martin, The Cleveland Clinic, Stuart L Fine, MD, Study Vice-Chair, University of Pennsylvania, Maureen G Maguire, PhD, Director of Coordinating Center, University of Pennsylvania, Glenn Jaffe, MD, Director of OCT Reading Center, Duke University, Juan E Grunwald, MD, Principal Investigator of Photography Reading Center, Universisty of Pennsylvania. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial. Retrieved March 1, 2010, from http://clinicaltrials.gov/ct2/results?term=ranibizumab+Bevacizumab&pg=2.
   Google Scholar